Bora Pharmaceuticals Co., Ltd. (TWSE: 6472; OTCQX: BORAY) announced today the completion of its acquisition of MacroGenics, Inc.'s (NASDAQ: MGNX) GMP manufacturing operations, including the biologics drug substance facility in Rockville, Maryland and an associated warehousing center in Frederick, Maryland, for a total consideration of $122.5 million. The transaction, conducted through Bora's wholly owned subsidiary Bora Biologics USA, LLC, also includes a long-term CDMO service agreement with MacroGenics.
With this acquisition, Bora Biologics, the biologics CDMO franchise of Bora Group, now operates 20,000 liters of single-use bioreactor (SUB) drug substance manufacturing capacity across two active US sites in Rockville, Maryland and San Diego, California, as well as a development facility in Zhubei, Taiwan. This expansion establishes a US biologics manufacturing platform that supports sponsors from development through licensed commercial supply.
Bobby Sheng, Chairman and CEO of Bora Group, stated, "This acquisition establishes a US biologics manufacturing platform that sponsors can depend on, from development through licensed commercial supply. As regulatory and supply chain dynamics continue to evolve, we expect biotech and pharmaceutical companies to increasingly seek manufacturing partners with US-based, inspection-proven infrastructure. Bora Biologics is designed to meet that need, offering a fully integrated, end-to-end biologics platform spanning drug substance and drug product capabilities."
The Rockville facility addition enables Bora Biologics to support more than 4 active commercial programs, with over 120 completed GMP batches and supply into multiple global markets including the US, EU, Japan, Canada, and the UK, along with fully integrated QC and analytical capabilities. Across its US network, Bora Biologics has completed five FDA inspections, including two at Rockville and one PMDA review in 2025, all with clean results. The combined platform has supported more than 33 biologics and 15 biosimilars, establishing a manufacturing base for biotech and pharmaceutical companies with reduced offshore dependency and domestically anchored infrastructure.
Bora Group intends to integrate its US drug substance capabilities with its existing sterile drug product capabilities over the next 12 to 18 months, offering a seamless, fully integrated development-through-commercial biologics solution. This move positions Bora to capitalize on the growing demand for US-based biologics manufacturing as supply chain and regulatory considerations drive sponsors toward domestic partners. For more information, visit Bora Pharmaceuticals or Bora CDMO.
